Biogen’s antisense ALS drug shows promise in early clinical trial

Preliminary results from a phase 1 trial showed that tofersen (BIIB067), which Biogen in licensed from Ionis Pharmaceuticals, was well tolerated in amyotrophic lateral sclerosis (ALS) patients. The results suggest the drug could slow the progression of the disease in people with a mutant SOD1 gene.